Corrigendum to “The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)” [Cancer Lett. 392 (1) (2017) 9–16]
Authors:
- 1 October 2019
- journal article
- correction
- Published by Elsevier in Cancer Letters
- Vol. 461, 155